Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of nipocalimab compared to placebo in adults with moderate to severe systemic lupus erythematosus SLE, a long-term autoimmune disease where the immune system attacks healthy tissues causing inflammation in various organs. This phase 3, randomized, double-blind study aims to determine how well nipocalimab works alongside standard care treatments in managing SLE symptoms and disease activity. Participants will receive either nipocalimab or placebo combined with standard care treatments during a 52-week double-blind period. After this, eligible participants from both groups can join an open-label extension where they will continue to receive nipocalimab until Week 156 or until the study intervention is stopped. This design allows comparison of nipocalimabs effects versus placebo and longer-term safety and effectiveness in an open-label setting. Throughout the study, participants undergo regular assessments including disease activity indexes, joint evaluations, and fatigue scores. Researchers will track the percentage of participants achieving a standard SLE response measure at Week 52 and monitor changes in oral glucocorticoid use, joint pain, and flare-free status. Safety and treatment adherence are closely monitored across study visits, with data collected up to 3 years for long-term evaluation.
Actively Recruiting
Researchers are evaluating bimekizumab administered intravenously compared to subcutaneous injection in adults with active psoriatic arthritis or active axial spondyloarthritis. The study aims to show that the intravenous method is not less effective than the subcutaneous method by assessing how the drug moves in the body over time. This is a Phase 1, open-label, randomized, parallel-group study focused on treatment. Participants will receive one of three dosing regimens of bimekizumab during a pharmacokinetics lead-in phase and continue with the same assigned regimen during the treatment period. The dosing regimens include intravenous and subcutaneous administration of bimekizumab at specified times. Subjects are randomized into one of two experimental arms reflecting different intravenous regimens or a third arm receiving the subcutaneous regimen. During the study, participants will be monitored for steady-state trough concentration of the drug at week 16. Safety is assessed by tracking treatment-emergent adverse events, serious adverse events, and any events leading to withdrawal from the study through week 29. The study duration extends to the end of safety follow-up, with regular assessments to evaluate drug levels and participant health under medical supervision.
Actively Recruiting
Researchers are evaluating how the study medicine PF-06823859 dazukibart works in adults with active idiopathic inflammatory myopathies, specifically dermatomyositis DM and polymyositis PM. These rare diseases cause muscle inflammation leading to muscle weakness and sometimes skin rash in DM. The study aims to assess the safety and effectiveness of dazukibart compared to placebo in people already receiving stable doses of corticosteroids or immunosuppressants. Participants will be randomly assigned to receive either dazukibart or a placebo via intravenous infusion every 4 weeks, starting from Day 1 to Week 48. Each infusion takes about 1 hour and is administered at the study site. The study uses a double-blind design, meaning neither participants nor researchers know who receives the active drug or placebo, allowing for an unbiased comparison. Participants will be involved in approximately 15 visits over about 13 months. During these visits, researchers will monitor muscle strength, skin symptoms, physical function, fatigue, itch severity, corticosteroid use, and overall improvement using various clinical scales and patient questionnaires. Safety will be closely followed throughout the study. The main outcome measure is the Total Improvement Score TIS evaluated at 24 weeks outside the US and 52 weeks within the US.
Actively Recruiting
Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.
Actively Recruiting
This research aims to provide continued access to the drug anifrolumab for participants who have completed a previous clinical study and are assessed by the Investigator to still benefit from ongoing treatment. The study focuses on monitoring the long-term safety and tolerability of anifrolumab in people with conditions including Systemic Sclerosis, Cutaneous Lupus, Myopathies, and Systemic Lupus Erythematosus. Participants must have received at least one dose of anifrolumab in the prior study and be considered suitable to continue treatment. Participants will receive anifrolumab in the same form and manner as in the parent trial, which may be via pre-filled syringe, pre-filled pen, or infusion. This is an open-label study without randomization, where all participants continue on anifrolumab until they meet study discontinuation criteria. Those with treatment gaps or on compassionate use can also enroll. The study enrollment visit occurs at the end of the parent study after all safety follow-up assessments are complete. Throughout the study, safety monitoring includes collecting data on serious and non-serious adverse events from the first dose until 12 weeks after the last dose of anifrolumab. Participants will be followed until they discontinue, with ongoing assessments of tolerability. The study duration extends until December 2032, allowing long-term observation of treatment effects and safety.
Actively Recruiting
Researchers are examining the effect of abelacimab compared to a placebo in patients with atrial fibrillation AF who are considered unsuitable for oral anticoagulation therapy. This Phase 3 study focuses on high-risk patients with AF to evaluate whether abelacimab can reduce the occurrence of ischemic stroke or systemic embolism. The study is led by Anthos Therapeutics, Inc. and aims to address treatment options in patients where traditional anticoagulation is deemed inappropriate. Participants are randomly assigned in equal numbers to receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once a month. The study consists of three periods a screening period lasting up to 60 days, a double-blind treatment period that continues until at least 111 patients experience a primary endpoint event, and an end-of-treatment visit. Following this, participants may enter a 30-day follow-up or an optional open-label extension to receive abelacimab, depending on eligibility and regulatory approval. During the study, participants undergo assessments to monitor stroke, systemic embolism, and bleeding events, with the primary outcomes measured up to 30 months. Safety is tracked by recording bleeding events classified by the Bleeding Academic Research Consortium. Secondary outcomes include cardiovascular and all-cause mortality and other thrombotic events. The study also involves regular monitoring and follow-up visits to assess efficacy and safety throughout the treatment and observation periods.